260 related articles for article (PubMed ID: 28679676)
1. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.
Tanajewski L; Harris R; Harman DJ; Aithal GP; Card TR; Gkountouras G; Berdunov V; Guha IN; Elliott RA
BMJ Open; 2017 Jul; 7(6):e015659. PubMed ID: 28679676
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of nonalcoholic steatohepatitis screening.
Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
[TBL] [Abstract][Full Text] [Related]
5. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population.
Park H; Yoon EL; Kim M; Kwon SH; Kim D; Cheung R; Kim HL; Jun DW
Liver Int; 2024 Apr; 44(4):944-954. PubMed ID: 38291809
[TBL] [Abstract][Full Text] [Related]
9. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia.
Serra-Burriel M; Graupera I; Torán P; Thiele M; Roulot D; Wai-Sun Wong V; Neil Guha I; Fabrellas N; Arslanow A; Expósito C; Hernández R; Lai-Hung Wong G; Harman D; Darwish Murad S; Krag A; Pera G; Angeli P; Galle P; Aithal GP; Caballeria L; Castera L; Ginès P; Lammert F;
J Hepatol; 2019 Dec; 71(6):1141-1151. PubMed ID: 31470067
[TBL] [Abstract][Full Text] [Related]
10. Long-term cost-effectiveness of collaborative care (vs usual care) for people with depression and comorbid diabetes or cardiovascular disease: a Markov model informed by the COINCIDE randomised controlled trial.
Camacho EM; Ntais D; Coventry P; Bower P; Lovell K; Chew-Graham C; Baguley C; Gask L; Dickens C; Davies LM
BMJ Open; 2016 Oct; 6(10):e012514. PubMed ID: 27855101
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.
Phisalprapa P; Supakankunti S; Charatcharoenwitthaya P; Apisarnthanarak P; Charoensak A; Washirasaksiri C; Srivanichakorn W; Chaiyakunapruk N
Medicine (Baltimore); 2017 Apr; 96(17):e6585. PubMed ID: 28445256
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis.
Asphaug L; Thiele M; Krag A; Melberg HO
Hepatology; 2020 Jun; 71(6):2093-2104. PubMed ID: 31595545
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
Sangha K; Chang ST; Cheung R; Deshpande VS
Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
[TBL] [Abstract][Full Text] [Related]
17. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
18. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
Laramée P; Brodtkorb TH; Rahhali N; Knight C; Barbosa C; François C; Toumi M; Daeppen JB; Rehm J
BMJ Open; 2014 Sep; 4(9):e005376. PubMed ID: 25227627
[TBL] [Abstract][Full Text] [Related]
20. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
